Oncolytics Biotech Inc ONCY

GSK drops the development of engineered cell therapy

[Noteable]

This development further places ONCY in a favourable position as pelareorep is able to remodel the tumor microenvironment and enhance T-cell clonality, and thus mitigating T-cell exhaustion, particularly when pelareorep is combined with an immune checkpoint inhibitor.

https://www.evaluate.com/vantage/articles/news/deals/gsk-deals-cell-therapy-another-setback

[Noteable]

October 25, 2022 - GSK is trimming back in cancer cell therapy research, disclosing plans to end partnerships with Lyell Immunopharma and Adaptimmune that were intended to develop immunotherapies for solid tumors. https://www.biopharmadive.com/news/gsk-terminates-lyell-adaptimmune-cell-therapy-deals/634900/

[Noteable]

October 26, 2022 - GSK has terminated its NY-ESO-1 T-cell receptor (TCR) pact with Lyell Immunopharma, with the Big Pharma transferring the program to Adaptimmune.  The winner from this decision appears to be Adaptimmune, which announced in a separate release today that it had gained possession of NY-ESO and another TCR T-cell program called PRAME. The

[Noteable]

October 27, 2022 - Bluebird spinout 2seventybio and China-based CAR-T company JW Therapeutics collaborate to build out a cell therapy platform with the aim of developing T cell receptor (TCR) therapies for solid tumors.  2seventy bio secured its legacy in the cell therapy arena by developing FDA-approved CAR-T Abecma with Bristol Myers. Meanwhile, JW Therapeutics has achieved cell

[Noteable]

November 01, 2022 - GSK's looming Zantac lawsuits raise doubts on the company's immediate M&A activities - as Wolfe Research analyst Tim Anderson suggested during a separate earnings call with investors. The uncertainty around the Zantac lawsuits means GSK might have to reserve money to resolve the legal liabilities. That could mean a temporary hold on dealmaking, especially

[Noteable]

November 09, 2022 - GSK's engineered cell therapy world continues to collapse - this time on the news on Adaptimmune's allogeneic cell therapy program change as reported below today. "Adaptimmune’s allogeneic MAGE-A4 program seemed to be near the finish line, with the company’s UK manufacturing facility almost done. The plan at the time was for the cell therapy to be ready for